The predictive capacity of in vitro preclinical models to evaluate drugs for the treatment of retinoblastoma
Open Access
- 20 March 2023
- journal article
- review article
- Published by Elsevier in Experimental Eye Research
- Vol. 230, 109447
Abstract
No abstract availableKeywords
Funding Information
- Horizon 2020 Marie Skłodowska-Curie Actions (754354)
- Horizon 2020
- Horizon 2020 Framework Programme
This publication has 111 references indexed in Scilit:
- Intravitreal chemotherapy for vitreous seeding in retinoblastoma: Recent advances and perspectivesSaudi Journal of Ophthalmology, 2013
- Tumorspheres but Not Adherent Cells Derived from Retinoblastoma Tumors Are of Malignant OriginPLOS ONE, 2013
- Antitumor activity of celastrol nanoparticles in a xenograft retinoblastoma tumor modelInternational Journal of Nanomedicine, 2012
- A novel retinoblastoma therapy from genomic and epigenetic analysesNature, 2012
- Sonoporation Enhances Chemotherapeutic Efficacy in Retinoblastoma Cells In VitroInvestigative Ophthalmology & Visual Science, 2011
- Treatment with connexin 46 siRNA suppresses the growth of human Y79 retinoblastoma cell xenografts in vivoExperimental Eye Research, 2011
- Conservative Treatments of Intraocular RetinoblastomaOphthalmology, 2008
- Cell Size Checkpoint Control by the Retinoblastoma Tumor Suppressor PathwayPLOS Genetics, 2006
- Integrating pharmacology and in vivo cancer models in preclinical and clinical drug developmentEuropean Journal of Cancer, 2004
- Mutation and Cancer: Statistical Study of RetinoblastomaProceedings of the National Academy of Sciences, 1971